Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-4.99 Insider Own64.50% Shs Outstand29.39M Perf Week7.00%
Market Cap388.29M Forward P/E- EPS next Y-3.66 Insider Trans0.30% Shs Float20.73M Perf Month28.13%
Income-238.30M PEG- EPS next Q-1.07 Inst Own38.01% Short Float / Ratio20.01% / 12.73 Perf Quarter-13.30%
Sales1.85M P/S209.89 EPS this Y11.05% Inst Trans-0.67% Short Interest4.15M Perf Half Y-37.38%
Book/sh4.35 P/B1.53 EPS next Y22.57% ROA-46.94% Target Price19.90 Perf Year-66.38%
Cash/sh6.64 P/C1.00 EPS next 5Y- ROE-81.88% 52W Range3.81 - 27.92 Perf YTD-60.91%
Dividend- P/FCF- EPS past 5Y-71.19% ROI-82.50% 52W High-76.18% Beta0.19
Dividend %- Quick Ratio9.27 Sales past 5Y0.00% Gross Margin-547.54% 52W Low74.54% ATR0.69
Employees258 Current Ratio9.27 Sales Q/Q53.78% Oper. Margin-13755.05% RSI (14)59.06 Volatility13.55% 13.47%
OptionableYes Debt/Eq0.16 EPS Q/Q21.06% Profit Margin-12873.96% Rel Volume1.20 Prev Close7.00
ShortableYes LT Debt/Eq0.14 EarningsNov 13 AMC Payout- Avg Volume325.99K Price6.65
Recom1.80 SMA2015.76% SMA5023.15% SMA200-33.01% Volume390,278 Change-5.00%
Date Action Analyst Rating Change Price Target Change
Dec-07-23Downgrade H.C. Wainwright Buy → Neutral $11 → $7
Nov-09-22Resumed Jefferies Buy $61 → $55
Oct-17-22Initiated JP Morgan Neutral $27
Aug-29-22Initiated BofA Securities Buy $34
Dec-13-21Downgrade RBC Capital Mkts Outperform → Sector Perform $51
Nov-05-21Upgrade Wedbush Neutral → Outperform
Aug-26-21Initiated Morgan Stanley Overweight $100
Jan-29-21Initiated RBC Capital Mkts Outperform $121
Jan-19-21Reiterated H.C. Wainwright Buy $88 → $114
Dec-22-20Downgrade Wedbush Outperform → Neutral
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
02:46AM Loading…
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
07:29AM Loading…
Oct-05-23 07:29AM
Oct-03-23 04:05PM
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
Jun-01-23 07:00AM
07:00AM Loading…
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
Jul-04-22 02:04PM
Jun-01-22 07:00AM
May-20-22 12:07PM
May-10-22 07:00AM
May-09-22 04:16PM
May-06-22 07:00AM
Apr-09-22 09:35AM
Apr-06-22 04:39PM
Apr-05-22 04:56PM
Mar-30-22 03:06PM
Mar-29-22 11:41AM
Feb-09-22 03:34PM
Feb-03-22 04:05PM
Jan-10-22 10:00AM
Jan-05-22 07:00AM
Dec-13-21 09:43AM
Dec-11-21 01:31PM
Dec-09-21 07:36AM
Dec-08-21 07:00AM
Dec-06-21 04:05PM
Nov-10-21 04:05PM
Nov-08-21 07:00AM
Nov-04-21 11:25AM
Oct-11-21 04:05PM
Oct-06-21 11:44AM
Sep-23-21 04:05PM
Sep-10-21 09:01AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Takimoto Chris HChief Medical OfficerNov 29Sale6.211,1807,33153,562Dec 01 07:03 PM
Decker Lisa LynnChief Business OfficerNov 29Sale6.211,1807,33140,001Dec 01 07:01 PM
Gauthier GeorgeChief Commercial OfficerNov 29Sale6.211,1807,33139,642Dec 01 07:02 PM
Tahir MisbahChief Financial OfficerNov 27Sale5.061,3376,76449,608Nov 29 08:49 PM
Schwarzer FredCEO and PresidentNov 27Sale5.061,3376,764120,424Nov 29 08:48 PM
Keyt BruceChief Scientific OfficerNov 27Sale5.069334,720137,125Nov 29 08:47 PM
Gauthier GeorgeChief Commercial OfficerOct 02Sale7.959357,43039,082Oct 03 07:55 PM
Gauthier GeorgeChief Commercial OfficerJul 03Sale9.429368,81840,017Jul 05 09:08 PM
Topsoe Jakob HaldorDirectorJun 30Buy9.253,50032,37581,644Jul 03 06:46 PM
Topsoe Christina TengDirectorJun 30Buy9.323,00027,9579,800Jul 05 09:07 PM
Redmile Group, LLCDirectorJun 29Buy9.4280,423757,5852,974,186Jul 03 09:45 PM
Topsoe Jakob HaldorDirectorJun 29Buy9.103,50031,84678,144Jul 03 06:46 PM
Redmile Group, LLCDirectorJun 29Sale9.4280,423757,5852,893,763Jul 03 09:45 PM
BEHRENS M KATHLEENDirectorJun 26Buy8.00112,500900,000330,700Jun 28 07:34 PM
Gauthier GeorgeChief Commercial OfficerMay 23Sale12.311,25915,49740,953May 25 07:20 PM
Decker Lisa LynnChief Business OfficerMay 23Sale12.311,25915,49741,181May 25 07:20 PM
Tahir MisbahChief Financial OfficerMay 23Sale12.311,25915,49750,711May 25 07:23 PM
Takimoto Chris HChief Medical OfficerMay 23Sale12.311,25915,49754,742May 25 07:24 PM
Schwarzer FredCEO and PresidentMay 23Sale12.311,25915,497121,761May 25 07:22 PM
Keyt BruceChief Scientific OfficerMay 23Sale12.3198212,088138,058May 25 07:21 PM
Gauthier GeorgeChief Commercial OfficerApr 05Sale12.6093511,78133,878Apr 06 09:39 PM
Takimoto Chris HChief Medical OfficerMar 14Sale18.731,76833,11828,789Mar 16 06:31 PM
Tahir MisbahChief Financial OfficerMar 14Sale18.731,76833,11825,322Mar 16 06:30 PM
Keyt BruceChief Scientific OfficerMar 14Sale18.731,29324,22090,704Mar 16 06:30 PM
Gauthier GeorgeChief Commercial OfficerMar 14Sale18.731,06119,87518,563Mar 16 06:28 PM
Decker Lisa LynnChief Business OfficerMar 14Sale18.731,06119,87516,732Mar 16 06:27 PM
Keyt BruceChief Scientific OfficerJan 05Option Exercise0.9333,75631,39391,997Jan 09 06:16 PM
Tahir MisbahChief Financial OfficerDec 19Sale20.003,80176,02027,090Dec 20 08:09 PM
Schwarzer FredCEO and PresidentDec 16Sale18.9812,369234,80520,360Dec 20 08:08 PM
Takimoto Chris HChief Medical OfficerDec 16Sale18.985,430103,08030,557Dec 20 08:12 PM
Keyt BruceChief Scientific OfficerDec 16Sale18.985,371101,96058,241Dec 20 08:07 PM
Gauthier GeorgeChief Commercial OfficerDec 16Sale18.984,35482,65419,624Dec 20 08:06 PM
Decker Lisa LynnChief Business OfficerDec 16Sale18.982,48447,15417,793Dec 20 08:05 PM
Tahir MisbahChief Financial OfficerDec 16Sale18.982,28343,33930,891Dec 20 08:09 PM
Keyt BruceChief Scientific OfficerDec 14Option Exercise0.9325,00023,25063,612Dec 16 07:40 PM